Isentress (raltegravir) is commonly prescribed as part of combination therapy for the management of HIV infection in adults and pediatric patients weighing at least 4 kg. It is used in both treatment-naive patients (those who have not previously received antiretroviral therapy) and treatment-experienced patients (those who have received prior antiretroviral therapy).
The 400mg tablet refers to the dosage strength of Isentress. Each tablet contains 400 milligrams of raltegravir.
Isentress works by inhibiting the integrase enzyme, which is essential for the replication of HIV. By blocking this enzyme, Isentress helps prevent the integration of viral DNA into the DNA of human cells, thereby slowing down the progression of HIV infection and reducing the viral load in the body.
Isentress is usually taken orally, with or without food, twice daily. The specific dosage and regimen may vary depending on various factors, including the patient?s medical history, other medications being taken, and the stage of HIV infection.
As with any medication, Isentress can cause side effects, though they are generally uncommon. Common side effects may include headache, nausea, diarrhea, fatigue, and insomnia. Serious side effects such as severe skin reactions or liver problems are rare but possible.
It?s important for healthcare providers to monitor patients receiving Isentress for any adverse reactions and to adjust the dosage or treatment regimen as needed. Isentress should always be used in combination with other antiretroviral medications as part of a comprehensive HIV treatment plan.